The Type 1 Alpha-1 Antitrypsin Deficiency Treatment market, a rare genetic disorder in which the body produces insufficient alpha-1 antitrypsin protein leading to lung and liver damage is growing steadily. The market growth is driven by increasing disease awareness, improved diagnostic screening, the launch of new therapies (including augmentation therapies, gene therapies, RNA-based...